Nicolette Jackson

StageBio: Your Strategic Partner for Risk-Mitigated Histopathology Drug development often stalls due to avoidable hurdles protocol pitfalls, staining variability, and technical artifacts that lead to costly study repeats and missed IND timelines. At StageBio, we don’t just process slides; we proactively resolve these risks. How We Move Your Program Forward: Risk Mitigation: We identify scientific and technical gaps early from protocol design to real-time necropsy oversight to reduce risk of avoidable and costly repeats. Expert Advocacy: Our team of 20+ board-certified pathologists acts as an extension of your team, ensuring every finding is robust enough to withstand FDA/EMA scrutiny. Regulatory Strength: We deliver audit-ready GLP/SEND-compliant packages, providing the high-quality data needed for confident "Go/No-Go" decisions. Global Scale: With facilities in the U.S. and Germany, we provide the specialized insight including advanced morphometry and stereology required to advance your drug or device to submission. 🟣 CRO Services: Consultancy & Review | Necropsy | Histology | Imaging | Pathology | Digital Pathology | Archiving 🟣 Sites: Frederick (US) | Maurertown (US) | Freiburg (Germany) ☑️ Book a call with our scientific team | Connect with a StageBio expert to discuss your study goals, timelines, and how our pathology support can help you deliver the quality data for your project.